For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
ORGANIZATION
Yakukeiren’s Direct Joint Purchasing System for Generic Drugs to Go into Full Operation in FY2013
The Alliance of Pharmacy Executives (Yakukeiren), a general incorporated association of small and medium-sized pharmacies, approved a draft business plan and budget for FY2013 at its third annual general meeting held on February 24 in Tokyo. The business plan calls…
To read the full story
ORGANIZATION
- Self-Medication and Proper Drug Pricing 2 Sides of the Same Coin: Professor
November 8, 2024
- Japan Wholesaler Group to Continue Stressing Plight of Supply Disruption
October 25, 2024
- Drug Therapy for Fetal Tachyarrhythmia Gets 1st Health Coverage in Japan
October 21, 2024
- Off-Year Price Revision Has Accomplished Mission: JPMA Exec
October 18, 2024
- JaDHA Inks MOU with DTA to Collaborate in DTx Push
October 16, 2024
Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…